Evidence

2019 exceptional surveillance of lung cancer: diagnosis and management (NICE guideline NG122)

How we made the decision

How we made the decision

Exceptionally, significant new evidence may mean an update of a guideline is agreed before the next scheduled check of the need for an update. The evidence might be a single piece of evidence, an accumulation of evidence or other published NICE guidance.

For details of the process and update decisions that are available, see ensuring that published guidelines are current and accurate in developing NICE guidelines: the manual.

Evidence

This surveillance report provides an overview of 10 studies published since the end of the search period for the original guideline which published in February 2005. The results of these studies were considered in detail to determine if there is an impact on guideline recommendations.

Views of topic experts

We considered the views of topic experts, including those who helped to develop the guideline.

Views of stakeholders

Because this was an exceptional surveillance review, we did not consult on the decision.

ISBN: 978-1-4731-3356-3


This page was last updated: